Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
R&D
Biotech
Vertex takes $379M hit tied to cancelled islet cell program
Vertex announced a $379 million impairment charge tied to its earlier discontinuation of a clinical-stage islet cell treatment for diabetes.
Gabrielle Masson
May 6, 2025 12:50pm
Recursion streamlines pipeline following merger with Exscientia
May 5, 2025 11:00am
Novartis culls ph. 2 knee pain trial testing anti-ADAMTS-5 asset
Apr 16, 2025 2:55pm
Pfizer sells San Diego R&D site for $255M
Apr 10, 2025 11:06am
Relay starts 3rd layoff wave in one year, shedding 70 staffers
Apr 4, 2025 11:30am
Sanofi snatches GSK R&D leader
Mar 31, 2025 1:26pm
